PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum
Authors:
Open Access
- 21 August 2021
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica
- Vol. 142 (5) , 841-857
Abstract
Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens.Keywords
Funding Information
- Deutsche Kinderkrebsstiftung (DKS 2015.01)
- Brain Tumour Charity (GN-000382)
- Bundesministerium für Forschung, Technologie und Raumfahrt
- Deutsches Krebsforschungszentrum (DKFZ)
This publication has 57 references indexed in Scilit:
- Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factorMYBL1Proceedings of the National Academy of Sciences, 2013
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomasNature Genetics, 2013
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and explorationBriefings in Bioinformatics, 2012
- Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomasNature Genetics, 2012
- Gata2 Is Required for Migration and Differentiation of Retinorecipient Neurons in the Superior ColliculusJournal of Neuroscience, 2011
- Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylationJournal of Clinical Investigation, 2011
- Integrative genomics viewerNature Biotechnology, 2011
- The PAX258 gene subfamily: A comparative perspectiveDevelopmental Dynamics, 2009
- Gata2is a tissue-specific post-mitotic selector gene for midbrain GABAergic neuronsDevelopment, 2009
- A novel zinc finger gene is fused to EWS in small round cell tumorOncogene, 2000